预约演示
更新于：2025-05-16
Enistimagene Setitucel/Damistimagene Matitucel
更新于：2025-05-16
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
关联
12
项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的临床试验NCT06782932
A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma
The purpose of this study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab and AGEN2373 in combination with GVAX (Arm 1) or mKRASvax (Arm 2) in surgically resectable pancreatic adenocarcinoma.
开始日期2025-06-01 |
申办/合作机构 |
NCT03767582
A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs).
The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and radiotherapy, and to see if this combination therapy enhances the infiltration of CD8+CD137+ cells in PDACs .
开始日期2019-12-12 |
申办/合作机构 |
NCT03153410
A Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas
The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.
开始日期2018-09-27 |
申办/合作机构 |
100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的临床结果
登录后查看更多信息
100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的转化医学
登录后查看更多信息
100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的专利（医药）
登录后查看更多信息
2
项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的文献（医药）2019-12-01·Journal for immunotherapy of cancer2区 · 医学
Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
2区 · 医学
ArticleOA
作者: Foley, Kelly ; Armstrong, Todd D ; Xia, Tao ; Kim, Victoria M ; Che, Xu ; Blair, Alex B ; Wolfgang, Christopher L ; Zheng, Lei ; Jaffee, Elizabeth M ; Soares, Kevin ; Muth, Stephen T ; Brockstedt, Dirk ; Kleponis, Jennifer ; Lauer, Peter
BACKGROUND:
Immune checkpoint inhibitors are not effective for pancreatic ductal adenocarcinoma (PDAC) as single agents. Vaccine therapy may sensitize PDACs to checkpoint inhibitor treatments. Annexin A2 (ANXA2) is a pro-metastasis protein, previously identified as a relevant PDAC antigen that is expressed by a GM-CSF-secreting allogenic whole pancreatic tumor cell vaccine (GVAX) to induce an anti-ANXA2 antibody response in patients with PDAC. We hypothesized that an ANXA2-targeting vaccine approach not only provokes an immune response but also mounts anti-tumor effects.
METHODS:
We developed a Listeria-based, ANXA2-targeting cancer immunotherapy (Lm-ANXA2) and investigated its effectiveness within two murine models of PDAC.
RESULTS:
We show that Lm-ANXA2 prolonged the survival in a transplant model of mouse PDACs. More importantly, priming with the Lm-ANXA2 treatment prior to administration of anti-PD-1 antibodies increased cure rates in the implanted PDAC model and resulted in objective tumor responses and prolonged survival in the genetically engineered spontaneous PDAC model. In tumors treated with Lm-ANXA2 followed by anti-PD-1 antibody, the T cells specific to ANXA2 had significantly increased INFγ expression.
CONCLUSIONS:
For the first time, a listeria vaccine-based immunotherapy was shown to be able to induce a tumor antigen-specific T cell response within the tumor microenvironment of a "cold" tumor such as PDAC and sensitize the tumor to checkpoint inhibitor therapy. Moreover, this combination immunotherapy led to objective tumor responses and survival benefit in the mice with spontaneously developed PDAC tumors. Therefore, our study supports developing Lm-ANXA2 as a therapeutic agent in combination with anti-PD-1 antibody for PDAC treatment.
2019-09-15·Clinical cancer research : an official journal of the American Association for Cancer Research1区 · 医学
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
1区 · 医学
Article
作者: Elizabeth M. Jaffee ; Andrew H. Ko ; Tony Reid ; Daniel A. Laheru ; Sandy Ferber ; Hedy Kindler ; Amanda Enstrom ; Nitya Nair ; Zev A. Wainberg ; Paul E. Oberstein ; Dung T. Le ; Todd Crocenzi ; Michael A Morse ; Aimee Murphy ; Vincent J Picozzi ; Noelle K. LoConte ; Herbert Zeh ; Erkut Borazanci ; Colin D. Weekes ; Dirk G Brockstedt ; Andrea Wang-Gillam ; Chan Whiting ; Benjamin Musher
Abstract:
Purpose::
Limited options exist for patients with advanced pancreatic cancer progressing after 1 or more lines of therapy. A phase II study in patients with previously treated metastatic pancreatic cancer showed that combining GVAX pancreas (granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells) with cyclophosphamide (Cy) and CRS-207 (live, attenuated Listeria monocytogenes expressing mesothelin) resulted in median overall survival (OS) of 6.1 months, which compares favorably with historical OS achieved with chemotherapy. In the current study, we compared Cy/GVAX + CRS-207, CRS-207 alone, and standard chemotherapy in a three-arm, randomized, controlled phase IIb trial.
Patients and Methods::
Patients with previously treated metastatic pancreatic adenocarcinoma were randomized 1:1:1 to receive Cy/GVAX + CRS-207 (arm A), CRS-207 (arm B), or physician's choice of single-agent chemotherapy (arm C). The primary cohort included patients who had failed ≥2 prior lines of therapy, including gemcitabine. The primary objective compared OS between arms A and C in the primary cohort. The second-line cohort included patients who had received 1 prior line of therapy. Additional objectives included OS between all treatment arms, safety, and tumor responses.
Results::
The study did not meet its primary efficacy endpoint. At the final study analysis, median OS [95% confidence interval (CI)] in the primary cohort (N = 213) was 3.7 (2.9–5.3), 5.4 (4.2–6.4), and 4.6 (4.2–5.7) months in arms A, B, and C, respectively, showing no significant difference between arm A and arm C [P = not significant (NS), HR = 1.17; 95% CI, 0.84–1.64]. The most frequently reported adverse events in all treatment groups were chills, pyrexia, fatigue, and nausea. No treatment-related deaths occurred.
Conclusions::
The combination of Cy/GVAX + CRS-207 did not improve survival over chemotherapy. (ClinicalTrials.gov ID: NCT02004262)See related commentary by Salas-Benito et al., p. 5435
2
项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的新闻（医药）2015-03-30
March 30, 2015
By
Riley McDermid
, BioSpace.com Breaking News Sr. Editor
Scrappy Bay Area clinical stage cancer therapy company
Aduro Biotech
is celebrating Monday, after announcing drug behemoth
Novartis AG
will pay $200 million upfront to gain a 2.7 percent equity stake in
Aduro
for $25 million, the companies said. Under the terms of the deal,
Novartis
will also pour in another $25 million investment, with
Aduro
eligible for an extra $500 million in milestone payments.
Novartis
made the deal primarily to gain access to
Aduro
’s promising STING (Stimulator of Interferon Genes) receptor technology. The deal will now give it the rights to the worldwide research, development and commercialization of novel immuno-oncology products derived from
Aduro
’s cyclic dinucleotide (CDN) approach to target STING.
“We are delighted to collaborate with
Aduro
. We believe this target is among the most exciting in oncology today, the drug candidate to be of the highest quality, and the talent of our new colleagues from
Aduro
to be fantastic,” said
Novartis
’
Mark C. Fishman, M.D.
, president of the
Novartis Institutes
for
BioMedical Research
. “We anticipate many clinical opportunities will be explored with the CDN approach, both directly and in combination with other agents.”
Aduro
has been riding high since January, after raking in $51.4 million in a Series D funding round from 11 investors including
OrbiMed
,
Franklin Advisers
,
Foresite Capital Management
,
Clough Capital Partners
,
Janus Capital Management
and
Jennison Associates
.
Leerink Partners
acted as bookrunners on the deal.
Berkeley, Calif.-based
Aduro
said it will use the investment for to expand its research and clinical development capabilities, as it attempts to roll out its immuno-oncology platform in 2015. The company is best known for its experimental combo of proprietary drugs CRS-207 and GVAX Pancreas, a mix that is attracting investor interest as it goes through ECLIPSE, a 240 patient Phase 2b clinical trial to treat metastatic pancreatic cancer.
The cocktail received a breakthrough therapy designation from the
U.S. Food and Drug Administration (FDA)
last year, a “golden ticket” which has investors circling around the company as it fast-tracks its drug program.
The startup last received a $55 million
Series C
round from
Morningside Group
and
Johnson & Johnson Development Corporation
, bringing its total investment so far to $143.4 million.
Aduro
has been focusing on developing a platform of live-attenuated double-deleted Listeria monocytogenes strains (or LADD) that it has engineered to jumpstart an immune response in cancer patients. Its lead drug, CRS-207, works by expressing the tumor-associated antigen mesothelin, which makes it useful for treating mesothelioma and pancreatic, lung, ovarian and gastric cancers.
“2014 was a watershed year for
Aduro
and this financing demonstrates investor confidence in our future,” said
Stephen Isaacs
, chairman, president and chief executive officer of
Aduro
.
Aduro
’s other primary candidate is GVAX Pancreas, a drug that is a type of GVAX vaccines produced from human cancer cell lines and created to target T cells as a way to boost cancer immunity. Most of the company’s research is based on cyclic dinucleotides (CDNs), which are naturally occurring molecules that target an immunity regulator, dubbed the STING receptor.
“Our accomplishments during the year, including demonstrating positive results in our pancreatic cancer and mesothelioma programs, receiving Breakthrough Therapy designation from the
FDA
for the combination of CRS-207 and GVAX Pancreas, and establishing two worldwide collaboration agreements with
Johnson and Johnson Innovation (
Janssen Biotech Inc.
)
for the development and commercialization of novel immunotherapies for prostate and lung cancers, have positioned us well to achieve our goal of providing patients with more effective and more tolerable alternatives to treat cancer,” he said. “
We look forward to completing enrollment in our Phase 2b ECLIPSE trial in patients with metastatic pancreatic cancer and further exploring the broad versatility and applicability of our LADD and CDN technologies in other cancers.”
Last October
Aduro
inked a $30 million deal with the
Johnson & Johnson Innovation Center
in California to help it develop its nascent lung cancer therapies, the company announced Thursday.
Under the terms of the pact,
Janssen Biotech Inc. (JNJ)
, part of the
Janssen Pharmaceutical Companies
of
Johnson & Johnson (JNJ)
, will receive an exclusive, worldwide license to several of the cancer drugs in
Aduro
’s LADD immunotherapy platform
Aduro
received a $30 million up front and as much as $817 million as it hits development, regulatory and commercialization milestones payments.
The company’s primary focus is experimental therapies using Listeria bacteria, which they genetically modify with disease-specific antigens. It had an earlier, existing partnership with
Johnson & Johnson
, but the larger company appears to be doubling down on the company as research evolves.
Aduro
lauded the agreement as a major step forward for the tiny biotech. The deal is still subject to clearance by American antitrust authorities under the
Hart-Scott-Rodino Act
.
“Since our initial agreement with
Janssen
in May [2014] year for new immunotherapies for prostate cancer, they have been terrific partners and we’ve established a strong collaboration focused on advancing our technologies forward in their licensed indications,” said Isaacs at the time.
Isaacs said
Aduro
continues to make progress with a broad array of immunotherapy platforms in a number of other oncology indications, including pancreatic cancer, mesothelioma and glioblastoma.
临床2期引进/卖出疫苗免疫疗法突破性疗法
2015-02-26
- Combination Immunotherapeutic Regimen Designed to Enhance Cancer
Fighting Competency of Immune Cells -
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro Biotech, Inc. today announced the initiation of an
investigator-sponsored Phase 2 clinical trial of the company’s
immuno-oncology product candidates GVAX Pancreas and CRS-207 in
combination with Bristol-Myers Squibb’s Opdivo (nivolumab), a monoclonal
antibody against programmed death-1 receptor (PD-1). The first patient
has been enrolled in the trial that will be conducted at up to five U.S.
clinical trial sites.
“For some time, we have recognized and embraced the power of combination
strategies for immuno-oncology and this trial will evaluate expanding
our lead combination to include Opdivo, the first-in-class anti-PD-1”
GVAX Pancreas and CRS-207 are designed to stimulate an immune response
against a tumor, and nivolumab is designed to remove an
immuno-suppressive mechanism that cancer cells have developed against
the immune system. Aduro believes the combination of CRS-207 and GVAX
Pancreas with nivolumab may improve clinical outcomes because of their
complementary mechanisms of action.
The randomized, controlled STELLAR trial (Safety and Therapeutic
Efficacy of Live-attenuated Listeria/GVAX with Anti-PD1
Regimen) will enroll approximately 88 adults with metastatic
pancreatic cancer who have had one prior chemotherapy regimen for
metastatic disease. The trial will include two arms: Arm A with
CRS-207/GVAX Pancreas vaccine and nivolumab and Arm B with CRS-207/GVAX
Pancreas vaccine. The primary objective of this study is to compare the
overall survival (OS) of patients in Arm A and Arm B. Secondary
endpoints include evaluation of clinical and immune response and safety.
For more information, please visit ClinicalTrials.gov (Identifier:
NCT02243371).
The trial is supported by Stand up to Cancer (SU2C)-Lustgarten
Foundation Pancreatic Cancer Convergence Dream Team Translational
Research; Pancreatic Cancer Action Network – AACR Research Acceleration
Network Grant, supported by Fredman Family Foundation; and Bristol-Myers
Squibb. SU2C is a program of the Entertainment Industry Foundation.
“For some time, we have recognized and embraced the power of combination
strategies for immuno-oncology and this trial will evaluate expanding
our lead combination to include Opdivo, the first-in-class anti-PD-1,”
said Stephen T. Isaacs, chairman, president and chief executive officer
of Aduro. “While we continue our efforts to evaluate GVAX Pancreas and
CRS-207 in our Phase 2b ECLIPSE trial as an effective treatment for
pancreatic cancer, we look forward to generating data in yet another
combination for potential future applications of our technologies.”
“The Pancreatic Cancer Action Network is thrilled to have provided
initial funding that has been leveraged for this important program,”
said Julie Fleshman, president and CEO of the Pancreatic Cancer Action
Network. “In an effort to double pancreatic cancer survival by 2020, we
are investing in projects that have the potential to improve the
treatment landscape of pancreatic cancer and ultimately increase
survival.”
“Stand Up To Cancer is excited not only that this immunotherapy clinical
trial has begun patient enrollment, one of the 120 clinical trials we
have launched or completed,” stated SU2C President and CEO Sung Poblete,
R.N, Ph.D., “but that it involves collaboration by two distinct
biotechnology firms to study the combination of two proprietary
immunotherapies. Stand Up To Cancer is proud to have facilitated this
level of multi-institutional and corporate collaboration, which is at
the core of SU2C’s research model and its mission to benefit cancer
patients faster.”
Last year, the U.S. Food and Drug Administration (FDA) granted
Breakthrough Therapy designation for Aduro’s pancreatic cancer
combination treatment consisting of CRS-207 and GVAX Pancreas. According
to the FDA, a Breakthrough Therapy designation is for a drug candidate
that treats a serious or life-threatening condition and for which
preliminary clinical evidence indicates that the drug may demonstrate
substantial improvement on a clinically significant endpoint over
available therapies.
Separately, Aduro is currently conducting a 240 patient Phase 2b
clinical trial (ECLIPSE;
identifier NCT02004262) in metastatic pancreatic cancer patients who
have received at least one line of therapy. The randomized, controlled
3-arm trial will involve approximately 20 clinical trial sites in the
United States and Canada and will evaluate the safety, immune response
and efficacy of the combination immunotherapy of GVAX Pancreas in
combination with CRS-207 compared to chemotherapy or to CRS-207 as a
monotherapy. The primary endpoint of the trial is overall survival.
About CRS-207
CRS-207 is one of a family of product candidates based on Aduro’s
live-attenuated, double-deleted (LADD) Listeria monocytogenes
immuno-oncology platform that are designed to induce potent innate and
adaptive immune responses. CRS-207 has been engineered to express the
tumor-associated antigen mesothelin, which is over-expressed in many
cancers including mesothelioma and pancreatic, non-small cell lung,
ovarian and gastric cancers.
About GVAX Pancreas
GVAX Pancreas is one of a family of GVAX vaccines derived from human
cancer cell lines that are genetically modified to express
granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune
system-stimulating cytokine. GVAX Pancreas is derived from human
pancreatic cancer cell lines and is designed to activate specific T cell
immunity to pancreatic cancer antigens, including mesothelin.
About the Stand Up To Cancer Initiative
Stand Up To Cancer (SU2C) raises funds to accelerate the pace of
research to get new therapies to patients quickly and save lives now.
SU2C, a program of the Entertainment Industry Foundation (EIF), a
501(c)(3) charitable organization, was established in 2008 by film and
media leaders who utilize the industry’s resources to engage the public
in supporting a new, collaborative model of cancer research, and to
increase awareness about cancer prevention as well as progress being
made in the fight against the disease. As SU2C’s scientific partner, the
American Association for Cancer Research (AACR) and a Scientific
Advisory Committee led by Nobel Laureate Phillip A. Sharp, PhD, conduct
rigorous, competitive review processes to identify the best research
proposals to recommend for funding, oversee grants administration, and
provide expert review of research progress.
About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is the national organization
creating hope in a comprehensive way through research, patient support,
community outreach and advocacy for a cure. The organization is leading
the way to increase survival for people diagnosed with this devastating
disease through a bold initiative — The Vision of Progress: Double
Pancreatic Cancer Survival by 2020. Together, we can Wage Hope in the
fight against pancreatic cancer by intensifying our efforts to heighten
awareness, raise funds for comprehensive private research, and advocate
for dedicated federal research to advance early diagnostics and better
treatments and increase chances of survival. For more information, go to .
About Aduro
Aduro Biotech, Inc. is a private, clinical-stage immuno-oncology company
focused on the development of technology platforms to stimulate an
immune response against cancer. Aduro’s lead platform is based on
proprietary strains of live-attenuated, double-deleted (LADD) Listeria
monocytogenes that induce a potent innate immune response and have
been engineered to express tumor-associated antigens to induce
tumor-specific T cell-mediated immunity. Aduro has received Breakthrough
Therapy designation from the FDA for its lead LADD regimen, CRS-207 in
combination with GVAX Pancreas in pancreatic cancer. The company is
evaluating the proprietary immuno-oncology combination in the ongoing
Phase 2b ECLIPSE clinical trial and has additional ongoing clinical
trials with its LADD platform in mesothelioma and glioblastoma. The
company is also developing clinical candidates using synthetic small
molecule immune modulators that are designed to activate the
intracellular STING receptor, a central mediator of the innate immune
response. For more information, please visit .
Contacts
Aduro Biotech, Inc.Sylvia Wheeler, 510-809-9264SVP,
Corporate AffairsorMedia Contact:Angela Bitting,
925-202-6211a.bitting@comcast.net
Help employers find you! Check out all the jobs and post your resume.
疫苗合作抗体突破性疗法First in Class
100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 局部晚期胰腺腺癌 | 临床2期 | 美国 | 2016-07-18 | |
| 腺癌 | 临床2期 | 美国 | 2015-01-02 | |
| 转移性胰腺癌 | 临床2期 | 美国 | 2011-09-21 | |
| 转移性胰腺腺癌 | 临床2期 | 美国 | 2011-09-21 | |
| 晚期胰腺腺癌 | 临床2期 | 美国 | 2005-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 61 | 襯鹹鹽鹽糧鏇餘築夢壓 = 膚齋艱築築獵獵繭醖築 齋艱鑰積廠窪糧網窪範 (廠製願構鹹觸蓋鏇觸範, 鬱鹹鹽鏇壓範餘襯憲築 ~ 餘窪繭鏇鏇醖鹽願壓醖) 更多 | - | 2023-07-10 | |||
临床2期 | 58 | 蓋艱積觸齋夢夢觸夢繭(選糧餘壓鑰築淵齋齋餘) = 鏇膚衊蓋廠範廠鹽廠鑰 鑰遞願艱艱繭壓糧顧憲 (夢遞遞簾鹹淵壓鏇蓋鬱, 顧膚艱襯顧網鑰鹽夢網 ~ 選製構選壓築醖構繭鏇) 更多 | - | 2023-02-28 | |||
临床2期 | 83 | (Ipilimumab + Vaccine) | 壓衊願壓淵鑰觸壓鬱艱(觸積衊積築淵壓網齋廠) = 築糧簾構膚膚鑰製積遞 蓋襯膚範積膚構構簾範 (齋範鑰齋餘築艱鏇艱願, 衊糧簾繭願鹹鏇淵憲願 ~ 觸鏇衊範願獵選憲築選) 更多 | - | 2020-05-06 | ||
FOLFIRINOX (FOLFIRINOX) | 壓衊願壓淵鑰觸壓鬱艱(觸積衊積築淵壓網齋廠) = 齋範獵觸憲鹽簾鬱衊鑰 蓋襯膚範積膚構構簾範 (齋範鑰齋餘築艱鏇艱願, 醖鹹築鏇醖構廠顧製鑰 ~ 衊蓋簾鏇顧廠齋築壓築) 更多 | ||||||
临床2期 | 93 | 鏇獵鬱淵簾衊獵積艱積(繭遞壓齋鏇顧艱鬱築製) = 艱餘衊遞壓蓋淵鬱構憲 觸網餘積觸願餘鹽鏇遞 (壓獵網繭鹹壓範鹹顧觸, 糧製齋鑰網遞壓壓簾憲 ~ 築糧廠獵鏇網壓鏇壓夢) 更多 | - | 2019-10-08 | |||
鏇獵鬱淵簾衊獵積艱積(繭遞壓齋鏇顧艱鬱築製) = 積衊膚製廠衊鏇鬱鑰簾 觸網餘積觸願餘鹽鏇遞 (壓獵網繭鹹壓範鹹顧觸, 淵製願齋鑰糧顧顧簾蓋 ~ 餘壓糧願鑰觸願齋齋鬱) 更多 | |||||||
临床2期 | 213 | Cy/GVAX + CRS-207 | 窪壓壓網製夢網膚壓選(積獵鹹壓夢簾蓋觸鏇網) = 膚製憲範鹹衊壓廠衊鏇 壓廠艱窪鹹膚餘鹽鑰壓 (衊獵構齋憲觸繭鏇鬱憲 ) | 不佳 | 2019-09-15 | ||
CRS-207 | 窪壓壓網製夢網膚壓選(積獵鹹壓夢簾蓋觸鏇網) = 襯憲觸窪網糧獵製築選 壓廠艱窪鹹膚餘鹽鑰壓 (衊獵構齋憲觸繭鏇鬱憲 ) | ||||||
临床2期 | 93 | (Cy/GVAX + CRS-207) | 獵願齋繭選鏇憲鏇鏇鏇(醖網觸選願積淵膚鬱齋) = 衊憲夢壓壓顧願構繭糧 網選範糧鑰憲齋廠鏇鏇 (築範願鏇網廠築鏇鏇簾, 願選簾範顧蓋夢壓醖蓋 ~ 齋淵膚醖鹽淵選構觸鹹) 更多 | - | 2018-05-08 | ||
(Cy/GVAX) | 獵願齋繭選鏇憲鏇鏇鏇(醖網觸選願積淵膚鬱齋) = 夢積選鹹觸範願願淵壓 網選範糧鑰憲齋廠鏇鏇 (築範願鏇網廠築鏇鏇簾, 鬱鬱構襯憲範選淵壓觸 ~ 壓積願築觸鹹範鏇鬱築) 更多 | ||||||
临床2期 | 303 | (Primary Cohort: Cy/GVAX + CRS-207) | 獵鑰鹽襯構構膚衊顧夢(網遞鬱繭淵積顧網蓋鹽) = 齋顧鹽鏇積網鹹築鑰蓋 醖齋鹹餘壓願夢膚廠網 (餘鬱衊艱齋糧艱鹽鏇觸, 衊淵構積餘鏇簾鬱襯遞 ~ 選壓鬱積憲艱築鹹淵蓋) 更多 | - | 2018-05-03 | ||
(Primary Cohort: CRS-207) | 獵鑰鹽襯構構膚衊顧夢(網遞鬱繭淵積顧網蓋鹽) = 淵鬱憲齋醖襯夢繭製糧 醖齋鹹餘壓願夢膚廠網 (餘鬱衊艱齋糧艱鹽鏇觸, 鏇製築齋範範獵選鑰齋 ~ 憲窪襯網醖衊網齋鹽構) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用